Atara Biotherapeutics, Inc. Q1 FY2021 earnings call

Pascal Touchon highlighted progress on strategic priorities: making progress on tab-cel, ATA188 in multiple sclerosis, and next-generation allogeneic CAR T programs. Discussed ongoing FDA discussions for tab-cel BLA and MAA filings, progress on ATA188 enrollment and data presentation, and CAR T portfolio progress including mesothelin programs with Bayer collaboration. Jakob Dupont discussed aligning with FDA on tab-cel comparability, progress on ATA188 enrollment and data presentation, and CAR-T program details with Bayer. Financials noted ending Q1 2021 with $435 million in cash and sufficient funding into 2023.

No detailed financial performance for product segments provided in the transcript.

Plans to complete tab-cel BLA submission in Q3 2021; ATA188 to conduct interim analysis of Phase 2 RCT in H1 2022 and present long-term data in H2 2021; mesothelin CAR T Phase 1 first cohort enrolled with data expected in Q4 2021; ATA3219 to submit IND in Q4 2021 or Q1 2022.

No specific risks discussed in detail in the transcript.

Q: Regarding tab-cel filing, John Newman asked about FDA discussions on patient numbers.

A: Jakob Dupont stated guidance holds number of patients in ALLELE sufficient for BLA, working on CMC Model 3; Pascal Touchon clarified data cut in Q2 for Module 5.

Q: On ATA188 interim data and FDA discussions, Salim Syed asked about program outlook and patient population.

A: AJ Joshi discussed alignment on patient population, potential sample size adjustment for pivotal intent based on interim analysis.

Q: On tab-cel BLA timing, Jonathan Miller asked about filing timeline and multi-cohort study.

A: Jakob Dupont discussed ongoing FDA interactions and plan to file in Q3; AJ Joshi noted multi-cohort study enrollment pace and data timeline.

Q: On mesothelin CAR T program, Jonathan Miller asked about data expectations.

A: Jakob Dupont said first cohort enrolled, collecting safety and response data with translational elements on cell persistence.

Q: On ATA188 commercial potential, Tessa Romero asked about partnering.

A: Pascal Touchon discussed ongoing discussions with companies for partnership to accelerate ATA188 development.

Q: On tab-cel comparability, Phil Nadeau asked about FDA discussions.

A: Jakob Dupont explained 15 lots analysis for comparability; Pascal Touchon gave example of lot number discussion with FDA.

Q: On resource allocation, Elizabeth Webster asked about program allocation.

A: Pascal Touchon outlined resource allocation for tab-cel commercialization, ATA188 partnering, and allo CAR T program progress.

Q: On commercialization plans for tab-cel, Ben Burnett asked about inventory and delivery.

A: Kristin Yarema mentioned 95% patient coverage with inventory; Joe Newell discussed minimal process changes for comparability.

Q: On ATA3219, Carly Kenselaar asked about program design.

A: Jakob Dupont explained rationale for PD-1 DNR and EBV T cell specificity in ATA3219's design